Usefulness of the adjusted Global Antiphospholipid Syndrome Score (aGAPSS) to determine thrombotic risk in a cohort of patients with primary antiphospholipid syndrome

Mostrar todas las versiones(2)

Abstract:  Objective: to assess the adjusted Global Antiphospholipid Syndrome Score (aGAPSS) instrument to estimate the risk of vascular thrombosis in primary antiphospholipid syndrome (pAPS). A retrospective study was done between 2013-2020, including patients with pAPS by Sy...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Quaglia , M I, Vigliano , M M, Tissera , YS, Maldini , C, Albiero, J A, Savio , V, Gobbi , C, Alba , P
Formato: Artículo revista
Publicado: Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021
Materias:
Primary Antiphospholipid Syndrome
GAPSS
thrombosis
Sindrome antifosfolipidico primario
trombosis
.
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/34942
Aporte de:
Revista de la Facultad de Ciencias Médicas de Córdoba de Universidad Nacional de Córdoba
id I10-R327-article-34942
record_format ojs
institution Universidad Nacional de Córdoba
institution_str I-10
repository_str R-327
container_title_str Revista de la Facultad de Ciencias Médicas de Córdoba
format Artículo revista
topic Primary Antiphospholipid Syndrome
GAPSS
thrombosis
Sindrome antifosfolipidico primario
GAPSS
trombosis
.
spellingShingle Primary Antiphospholipid Syndrome
GAPSS
thrombosis
Sindrome antifosfolipidico primario
GAPSS
trombosis
.
Quaglia , M I
Vigliano , M M
Tissera , YS
Maldini , C
Albiero, J A
Savio , V
Gobbi , C
Alba , P
Usefulness of the adjusted Global Antiphospholipid Syndrome Score (aGAPSS) to determine thrombotic risk in a cohort of patients with primary antiphospholipid syndrome
topic_facet Primary Antiphospholipid Syndrome
GAPSS
thrombosis
Sindrome antifosfolipidico primario
GAPSS
trombosis
.
author Quaglia , M I
Vigliano , M M
Tissera , YS
Maldini , C
Albiero, J A
Savio , V
Gobbi , C
Alba , P
author_facet Quaglia , M I
Vigliano , M M
Tissera , YS
Maldini , C
Albiero, J A
Savio , V
Gobbi , C
Alba , P
author_sort Quaglia , M I
title Usefulness of the adjusted Global Antiphospholipid Syndrome Score (aGAPSS) to determine thrombotic risk in a cohort of patients with primary antiphospholipid syndrome
title_short Usefulness of the adjusted Global Antiphospholipid Syndrome Score (aGAPSS) to determine thrombotic risk in a cohort of patients with primary antiphospholipid syndrome
title_full Usefulness of the adjusted Global Antiphospholipid Syndrome Score (aGAPSS) to determine thrombotic risk in a cohort of patients with primary antiphospholipid syndrome
title_fullStr Usefulness of the adjusted Global Antiphospholipid Syndrome Score (aGAPSS) to determine thrombotic risk in a cohort of patients with primary antiphospholipid syndrome
title_full_unstemmed Usefulness of the adjusted Global Antiphospholipid Syndrome Score (aGAPSS) to determine thrombotic risk in a cohort of patients with primary antiphospholipid syndrome
title_sort usefulness of the adjusted global antiphospholipid syndrome score (agapss) to determine thrombotic risk in a cohort of patients with primary antiphospholipid syndrome
description Abstract:  Objective: to assess the adjusted Global Antiphospholipid Syndrome Score (aGAPSS) instrument to estimate the risk of vascular thrombosis in primary antiphospholipid syndrome (pAPS). A retrospective study was done between 2013-2020, including patients with pAPS by Sydney criteria. The presence of arterial and venous thrombosis (tAPS), obstetrical comorbidity (oAPS), non-criteria manifestations (NCM), antiphospholipid antibodies (APLA), recurrent thrombosis and mortality were evaluated. Patients were grouped in tAPS, oAPS or both; the last one was used when the stratification was done. In the first visit, aGAPSS was calculated by adding: arterial hypertension: 1, hyperlipidemia: 3, moderate-high titles of anti-cardiolipin antibody (aCL): 5, anti-β2glicoprotein I (aB2GPI): 4 and lupus anticoagulant (LA): 4. aGAPSS ≥ 10 was considered high. Results: 85 patients entered the study, 74,11% completed the follow-up. 87,1% were women, mean age was 36 years (32,75-40,25), illness of 53 months (25-114). 62,35% had oAPS, 24,5% tAPS and 12,94% both. There were 18 arterial thrombosis, 11 venous thrombosis and 3 in both sites. Patients with tAPS had longer illness (p=0,04), higher rates of aB2GP1 (p=<0,001) and triple positivity (p=0,0003). The mean aGAPSS was 9 (5-12); in tAPS the mean value was 9 (8,75-13) and in oAPS 9 (5-9); p=0,008. There was no difference between patients with criteria manifestations and NCM. New trombosis (12,69%) happened in tAPS; the mean time was 26 months (15-49). There were 4 arterial thrombosis, 2 venous thrombosis and 2 in both sites. The mean aGAPSS in patients with recurrence was 13 (9-13), 62,50% had aGAPSS ≥ 10; and 87% had MNC. 4 (6,34%) patients died, all of them with recurrent thrombosis. aGAPSS ≥ 10 predicted new thrombosis (p=0,016). Patients with recurrence had a worse survival curve (p= 0,00000). Conclusion: assessing the risk of thrombosis in APS with aGAPSS could identify individuals at high risk of recurrence, monitor them, and intervene to prevent future events.
publisher Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
publishDate 2021
url https://revistas.unc.edu.ar/index.php/med/article/view/34942
work_keys_str_mv AT quagliami usefulnessoftheadjustedglobalantiphospholipidsyndromescoreagapsstodeterminethromboticriskinacohortofpatientswithprimaryantiphospholipidsyndrome
AT viglianomm usefulnessoftheadjustedglobalantiphospholipidsyndromescoreagapsstodeterminethromboticriskinacohortofpatientswithprimaryantiphospholipidsyndrome
AT tisserays usefulnessoftheadjustedglobalantiphospholipidsyndromescoreagapsstodeterminethromboticriskinacohortofpatientswithprimaryantiphospholipidsyndrome
AT maldinic usefulnessoftheadjustedglobalantiphospholipidsyndromescoreagapsstodeterminethromboticriskinacohortofpatientswithprimaryantiphospholipidsyndrome
AT albieroja usefulnessoftheadjustedglobalantiphospholipidsyndromescoreagapsstodeterminethromboticriskinacohortofpatientswithprimaryantiphospholipidsyndrome
AT saviov usefulnessoftheadjustedglobalantiphospholipidsyndromescoreagapsstodeterminethromboticriskinacohortofpatientswithprimaryantiphospholipidsyndrome
AT gobbic usefulnessoftheadjustedglobalantiphospholipidsyndromescoreagapsstodeterminethromboticriskinacohortofpatientswithprimaryantiphospholipidsyndrome
AT albap usefulnessoftheadjustedglobalantiphospholipidsyndromescoreagapsstodeterminethromboticriskinacohortofpatientswithprimaryantiphospholipidsyndrome
AT quagliami utilidaddelglobalantiphospholipidsyndromescoreajustadoagapssparadeterminarelriesgotromboticoenunacohortedepacientesconsindromeantifosfolipidoprimario
AT viglianomm utilidaddelglobalantiphospholipidsyndromescoreajustadoagapssparadeterminarelriesgotromboticoenunacohortedepacientesconsindromeantifosfolipidoprimario
AT tisserays utilidaddelglobalantiphospholipidsyndromescoreajustadoagapssparadeterminarelriesgotromboticoenunacohortedepacientesconsindromeantifosfolipidoprimario
AT maldinic utilidaddelglobalantiphospholipidsyndromescoreajustadoagapssparadeterminarelriesgotromboticoenunacohortedepacientesconsindromeantifosfolipidoprimario
AT albieroja utilidaddelglobalantiphospholipidsyndromescoreajustadoagapssparadeterminarelriesgotromboticoenunacohortedepacientesconsindromeantifosfolipidoprimario
AT saviov utilidaddelglobalantiphospholipidsyndromescoreajustadoagapssparadeterminarelriesgotromboticoenunacohortedepacientesconsindromeantifosfolipidoprimario
AT gobbic utilidaddelglobalantiphospholipidsyndromescoreajustadoagapssparadeterminarelriesgotromboticoenunacohortedepacientesconsindromeantifosfolipidoprimario
AT albap utilidaddelglobalantiphospholipidsyndromescoreajustadoagapssparadeterminarelriesgotromboticoenunacohortedepacientesconsindromeantifosfolipidoprimario
AT quagliami a
AT viglianomm a
AT tisserays a
AT maldinic a
AT albieroja a
AT saviov a
AT gobbic a
AT albap a
first_indexed 2024-09-03T21:02:49Z
last_indexed 2024-09-03T21:02:49Z
_version_ 1809210272597934080
spelling I10-R327-article-349422024-04-15T16:19:09Z Usefulness of the adjusted Global Antiphospholipid Syndrome Score (aGAPSS) to determine thrombotic risk in a cohort of patients with primary antiphospholipid syndrome Utilidad del Global Antiphospholipid Syndrome Score ajustado (aGAPSS) para determinar el riesgo trombótico en una cohorte de pacientes con Síndrome Antifosfolipído primario A Quaglia , M I Vigliano , M M Tissera , YS Maldini , C Albiero, J A Savio , V Gobbi , C Alba , P Primary Antiphospholipid Syndrome GAPSS thrombosis Sindrome antifosfolipidico primario GAPSS trombosis . Abstract:  Objective: to assess the adjusted Global Antiphospholipid Syndrome Score (aGAPSS) instrument to estimate the risk of vascular thrombosis in primary antiphospholipid syndrome (pAPS). A retrospective study was done between 2013-2020, including patients with pAPS by Sydney criteria. The presence of arterial and venous thrombosis (tAPS), obstetrical comorbidity (oAPS), non-criteria manifestations (NCM), antiphospholipid antibodies (APLA), recurrent thrombosis and mortality were evaluated. Patients were grouped in tAPS, oAPS or both; the last one was used when the stratification was done. In the first visit, aGAPSS was calculated by adding: arterial hypertension: 1, hyperlipidemia: 3, moderate-high titles of anti-cardiolipin antibody (aCL): 5, anti-β2glicoprotein I (aB2GPI): 4 and lupus anticoagulant (LA): 4. aGAPSS ≥ 10 was considered high. Results: 85 patients entered the study, 74,11% completed the follow-up. 87,1% were women, mean age was 36 years (32,75-40,25), illness of 53 months (25-114). 62,35% had oAPS, 24,5% tAPS and 12,94% both. There were 18 arterial thrombosis, 11 venous thrombosis and 3 in both sites. Patients with tAPS had longer illness (p=0,04), higher rates of aB2GP1 (p=<0,001) and triple positivity (p=0,0003). The mean aGAPSS was 9 (5-12); in tAPS the mean value was 9 (8,75-13) and in oAPS 9 (5-9); p=0,008. There was no difference between patients with criteria manifestations and NCM. New trombosis (12,69%) happened in tAPS; the mean time was 26 months (15-49). There were 4 arterial thrombosis, 2 venous thrombosis and 2 in both sites. The mean aGAPSS in patients with recurrence was 13 (9-13), 62,50% had aGAPSS ≥ 10; and 87% had MNC. 4 (6,34%) patients died, all of them with recurrent thrombosis. aGAPSS ≥ 10 predicted new thrombosis (p=0,016). Patients with recurrence had a worse survival curve (p= 0,00000). Conclusion: assessing the risk of thrombosis in APS with aGAPSS could identify individuals at high risk of recurrence, monitor them, and intervene to prevent future events. Resumen:  Objetivo: valorar el instrumento Global Antiphospholipid Sydrome Score ajustado (aGAPSS) para estimar riesgo de trombosis vascular en SAF primario (SAFP). Se realizó un estudio retrospectivo incluyendo pacientes con SAFP (criterios de Sydney) entre 2013 y 2020 de Hospital Materno-neonatal y Córdoba. Se analizaron: trombosis venosa y arterial (SAFT), morbilidad obstétrica (SAFO), manifestaciones no criterio (MNC), anticuerpos antifosfolípidos (AAF), recurrencia de trombosis y mortalidad. Se agruparon en SAFT, SAFO o ambas; el último grupo se utilizó para estratificación del riesgo. En visita basal calculamos aGAPPS sumando: HTA: 1, dislipemia: 3, anticuerpos anticardiolipinas (ACA) IgM/IgG títulos moderados-altos: 5, anticuerpos antibeta2glicoproteína I (ABGPI): 4 y anticoagulante lúpico (AL): 4. Se consideró aGAPSS alto  ≥ 10. Las variables continuas se expresaron como mediana y rango intercuartil; las categóricas como frecuencia y porcentaje. Se utilizó el test de Fisher para variables categóricas y test de Wilcoxon para variables mensurables. p < 0,05 fueron significativos. Aprobado por CIEIS del Adulto. Resultados: Ingresaron 85 pacientes, 74,11% completaron seguimiento. 87,1% mujeres, mediana de edad 36 años (32,75-40,25). 62,35% presentaban SAFO, 24,5% SAFT y 12,94% ambas. Presentaron 18 trombosis arteriales, 11 venosas y 3 en ambos sitios. Pacientes con SAFT tuvieron mayor duración de enfermedad (p=0,04), mayores tasas de ABGP1 (p=<0,001) y triple positividad (p=0,0003). La mediana del aGAPSS fue de 9 (5-12). En SAFT la mediana fue 9 (8,75-13) y en SAFO 9 (5-9); p=0,008. No hubo diferencia entre pacientes con manifestaciones criterio vs MNC. Las nuevas trombosis 12,69% ocurrieron en SAFT; la mediana del tiempo fue 26 meses (15-49). 4 fueron arteriales, 2 venosas y 2 ambas. La mediana de aGAPSS en pacientes con recurrencia fue 13 (9-13), 62,50% con GAPSS ≥ 10; y 87% presentaron MNC. 4 (6,34 %) pacientes fallecieron, todos con retrombosis. aGAPSS ≥ 10 predijo nuevas trombosis (p=0,016). Los pacientes con retrombosis tuvieron peor curva de sobrevida (p= 0,00000). Conclusión: La valoración del riesgo de trombosis en SAF con aGAPSS permitiría identificar individuos con alto riesgo de recurrencia, monitorizarlos e intervenir para prevenir futuros eventos. . Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021-10-12 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion texto texto texto https://revistas.unc.edu.ar/index.php/med/article/view/34942 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 78 No. Suplemento (2021): Suplemento JIC XXII Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 78 Núm. Suplemento (2021): Suplemento JIC XXII Revista da Faculdade de Ciências Médicas de Córdoba; v. 78 n. Suplemento (2021): Suplemento JIC XXII 1853-0605 0014-6722 http://creativecommons.org/licenses/by-nc/4.0

Ejemplares similares